PURPOSE Acquired resistance to anti–epidermal growth factor receptor (EGFR) inhibitor (EGFRi)
therapy in colorectal cancer (CRC) has previously been explained by the model of …

This co-clinical trial of combined MEK-CDK4/6 inhibition in RAS mutant colorectal cancer
demonstrates therapeutic efficacy in patient-derived xenografts and safety in patients, identifies …

Purpose: Encorafenib + cetuximab (E+C) is an effective therapeutic option in chemorefractory
BRAF V600E metastatic colorectal cancer (mCRC). However, there is a need to improve …

If you are inspired to collaborate with others to effect positive change in the world, this book
is for you. Collaboration using open-source technologies makes it possible to create new …

Designing studies of immunotherapy is limited due to a lack of pre-clinical models that
reliably predict effective immunotherapy responses. To address this gap, we developed …

This study examines the impact of inclusion on secondary students by focusing on the
performance of students without disabilities in the inclusive environment compared to their …

In this article, the authors investigate the achievement gap in the context of a particular region
and the factors associated with student learning in that region. Data were collected over …

Objective. Validated gastrointestinal (GI) symptoms scales are used in clinical practice to
assess patient-reported GI involvement. We sought to determine whether University of …

Over the past four-years the UK Arts and Humanities Research Council Knowledge Exchange
Hub, Design in Action (DiA), has developed a model of design as a strategy for economic …

Purpose: Encorafenib + cetuximab (E+C) is an effective therapeutic option in chemorefractory
BRAFV600E metastatic colorectal cancer (mCRC). However, there is a need to improve …